par Piccart-Gebhart, Martine 
;Hortobagyi, Gabriel N.;Campone, Mario;Pritchard, Kathleen;Lebrun, Fabienne;Ito, Y;Noguchi, Shinzaburo;Perez, A.;Rugo, Hope;Deleu, Ines;Burris, Howard A;Provencher, Louise;Neven, P;Gnant, Michael;Shtivelband, Mikhail;Wu, C;Fan, J;Feng, Wentao;Taran, Tetiana;Baselga, José
Référence Annals of oncology, 25, 12, page (2357-2362)
Publication Publié, 2014-12
;Hortobagyi, Gabriel N.;Campone, Mario;Pritchard, Kathleen;Lebrun, Fabienne;Ito, Y;Noguchi, Shinzaburo;Perez, A.;Rugo, Hope;Deleu, Ines;Burris, Howard A;Provencher, Louise;Neven, P;Gnant, Michael;Shtivelband, Mikhail;Wu, C;Fan, J;Feng, Wentao;Taran, Tetiana;Baselga, JoséRéférence Annals of oncology, 25, 12, page (2357-2362)
Publication Publié, 2014-12
Article révisé par les pairs
| Résumé : | The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR(+)), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analysis is presented here. |
